Information  X 
Enter a valid email address

PureTech Health PLC (PRTC)

  Print      Mail a friend

Thursday 23 February, 2017

PureTech Health PLC

PureTech Health Appoints Atul Pande as CMO

RNS Number : 6119X
PureTech Health PLC
23 February 2017
 

23 February 2017

PureTech Health plc

 

PureTech Health Appoints Atul Pande M.D., Former SVP at GlaxoSmithKline, as Chief Medical Officer

PureTech Health plc ("PureTech" or the "Company", LSE: PRTC), a cross-disciplinary biopharmaceutical company, today announced the appointment of Atul Pande, M.D., as the Company's Chief Medical Officer. In this new role, Dr. Pande will oversee all clinical operations across PureTech Health's pipeline and work closely with the team to de-risk and advance opportunities that hold the most potential for patients.

 

Dr. Pande commented: "I am proud and delighted to join this stellar team and hope to be instrumental in enabling the launch of some of the truly innovative medicines in the PureTech Health pipeline. Having been involved in clinical research and development for more than twenty years, I believe that the PureTech Health approach - which starts with ground-breaking science and signals of human efficacy and stresses safety - has important advantages."

 

"We are excited to work more closely with Atul and to have access to his drug development expertise across PureTech Health's pipeline," said Daphne Zohar, Chief Executive Officer of PureTech Health. "Atul is a seasoned drug development veteran who will help to shepherd our advancing pipeline through mid- and late-stage clinical trials while ensuring that synergies are leveraged across our platforms." 

 

Dr. Pande has more than two decades of experience in drug development. He is the former Senior Vice President, Head of Neuroscience, and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline.  Dr. Pande has been active in the development of multiple investigational and now marketed drugs while holding various senior roles in Pfizer R&D, Parke-Davis/Warner-Lambert, and Lilly Research Laboratories. His experience includes drug development, registration, launch and lifecycle management in the areas of anxiety, depression, epilepsy, neuropathic pain, schizophrenia, traumatic brain injury, and Alzheimer's and Parkinson's diseases. Dr. Pande is a psychiatrist and fellow of several scientific societies, including the American Psychiatric Association. He currently serves on the Board of Directors of PureTech's Karuna Pharmaceuticals. He also sits on the Board of Axovant Sciences (NYSE:AXON), and Autifony Therapeutics and on the Scientific Advisory Board of Cennerv Pharma. Dr. Pande began his career as a faculty member at the University of Michigan Medical School where his research focused on mood disorders. He has published over 50 peer-reviewed scientific papers and over 100 abstracts, book chapters, and book reviews.

 

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is a cross-disciplinary biopharmaceutical company creating 21st century medicines that modulate the adaptive human systems. Our therapies target the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. We have multiple human proof-of-concept studies and pivotal or registration studies expected to read out in the next two years. PureTech Health's rich and growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts who, along with PureTech's experienced team and board, analyse more than 650 scientific discoveries per year to identify and advance only the opportunities we believe hold the most promise for patients. This team and process place PureTech Health on the cutting edge of ground-breaking science and technological innovation and leads the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter.

 

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

For further information:

 

 

Media:

PureTech Health

Allison Mead

+1 617 651 3156

[email protected]

 

FTI Consulting

Ben Atwell

+44 (0) 20 3727 1000

Investors:

Graham Morrell

+1 617 986 1659

[email protected]

 

 

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUUSARBSAUUUR

a d v e r t i s e m e n t